CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
Question
CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
Direct answer
CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers. — bullish pressure on VRTX.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-expands-casgevy-label-to-pediatric-patients-as-q2-sales-hit-dcdb47
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| VRTX | ▲Bull | 1–3 months | Policy Shift | 72 |
CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M
CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers. — bullish pressure on VRTX.
CRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers.
- SummaryCRISPR Therapeutics recorded $76 million in second-quarter Casgevy revenue, marking a 78% sequential increase as commercial adoption scales in sickle cell disease and transfusion-dependent beta-thalassemia. Commercial upside was reinforced by FDA approval expanding Casgevy's indication to pediatric patients aged two and older, widening the eligible commercial population and providing durable therapy uptake across specialized treatment centers.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 521.12 2026-09-09 | -1.26% | -1.51% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.